Australian Clinical Labs (ASX:ACL) Net Issuance of Preferred Stock : A$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Australian Clinical Labs's net issuance of preferred for the six months ended in Dec. 2023 was A$0.0 Mil. The number is 0, which means that Australian Clinical Labs has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Australian Clinical Labs's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.0 Mil.

Australian Clinical Labs Net Issuance of Preferred Stock Historical Data

The historical data trend for Australian Clinical Labs's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Net Issuance of Preferred Stock Chart

Australian Clinical Labs Annual Data

Trend

Dec20

Jun21

Jun22

Jun23

Net Issuance of Preferred Stock

Australian Clinical Labs Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial			-	-	-	-	-

Australian Clinical Labs Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.0 Mil.

Australian Clinical Labs Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs (ASX:ACL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines